CCCC FY 2024 Earnings — C4 Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CCCCC4 Therapeutics, Inc.

$243M

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$36M+71.4% YoY

Gross Profit

$36M100.0% margin

Operating Income

-$120M-336.1% margin

Net Income

-$105M-296.0% margin

EPS (Diluted)

$-1.52

Cash Flow

Operating Cash Flow

-$65M

Free Cash Flow

-$65M

Stock-Based Comp.

$30M

Balance Sheet

Total Assets

$350M

Total Liabilities

$134M

Stockholders' Equity

$216M

Cash & Equivalents

$55M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$36M	$21M	+71.4%
Gross Profit	$36M	$13M	+173.3%
Operating Income	-$120M	-$139M	+14.0%
Net Income	-$105M	-$132M	+20.5%